Equity Details
Price & Market Data
Price: $0.593
Daily Change: -$0.003 / 0.51%
Daily Range: $0.59 - $0.615
Market Cap: $12,008,765
Daily Volume: 53,421
Performance Metrics
1 Week: -1.41%
1 Month: -15.07%
3 Months: -31.84%
6 Months: -37.26%
1 Year: -18.78%
YTD: -25.03%
About Trinity Biotech plc (TRIB)
Stay updated on Trinity Biotech plc (TRIB). Price: 0.593, daily change: -$0.003 / 0.51%. Market cap: 12,008,765. Performance YTD, 1-week, and 52-week are key.
Company Details
Employees: 287
Sector: Health technology
Industry: Medical specialties
Country: Ireland
Details
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to aggressive forms of the disease. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.